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Abstract
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Recently, the spectacular progress in diagnosis, treatment, and prognosis of different
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Available online: 30th Sept. 2022 malignancies has increased the demands on fertility preservation. Fertility impairment is

considered one of the complications of radio/cytotoxic treatments in females who
Keywords

managed to overcome their cancer. This issue of fertility preservation also concerns
those who are at risk of developing ovarian failure as well as healthy individuals who



Female

aim to overcome age-related fertility decline. Regarding female fertility preservation,



Fertility

there are various options that could be selected according to various factors, including



Preservation



the patient’s age, type of the disease, as well as type and urgency of treatment. Among

Techniques



Modalities

these options, embryo/oocyte cryopreservation as well as ovarian tissue cryopreservation
and autotransplantation are the most reliable modalities for post- and pre- pubertal
patients, respectively. Moreover, novel techniques such as the artificial ovary, isolation
and cryopreservation of follicles and immature oocyte, potential pharmacological
gonadoprotective agents, and stem cells transplantation have the potential to be used in
the future. In this article, current and future female fertility preservation strategies are
highlighted.
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Introduction
The preservation of female fertility is an important

and are now routinely used in assisted reproductive

issue for young people at risk of becoming infertile

further investigations[4].

due to diseases, treatments or simply ovarian
[1]

dysfunction due to aging .

technology (ART) centers, while others still need

Nowadays, the concept of fertility preservation
has assumed greater importance. Therefore, this

Infertility after cancer treatments is one of the

review will discuss the current and future female

major concerns for females with a history of

fertility preservation strategies and highlight their

[2]

cancer . It is well recognized that chemotherapy

advantages and disadvantages.

and radiotherapy are greatly toxic to the ovaries,

Indications for female fertility preservation

exposing pre-pubertal

girls

and

women of

Fertility preservation techniques can be offered

childbearing age to an increased risk of premature

to those who are at risk of infertility whatever the

ovarian insufficiency (POI) with subsequent

underlying etiology, whether malignancy, benign

[2]

infertility .

disorders, or social reasons[1].

Advancements

in

the

diagnosis

and

management of various cancers have dramatically

Malignant diseases
One of the terrible long-term side effects of

improved the survival rates. However, such

cancer

improvement has to be accompanied by a decrease

chemotherapy

in the adverse effects of treatments as well as an

Chemotherapeutic drugs, particularly alkylating

improvement in the quality of life of cancer

agents have shown to cause a high gonadal toxicity

survivors. Therefore, the development of fertility

in females resulting in follicular loss, amenorrhea,

preservation

techniques

gives

patients

and infertility[2]. Radiotherapy is not only capable

appropriate

choices

before

undergoing

of causing ovarian damage, but also can cause a

the

[1]

gonadotoxic treatments .

arthritis

erythematosus

as

or

in

females,

radiotherapy,

whether
is

POI[2].

decrease in uterine vascularity and volume,

Furthermore, autoimmune conditions such as
rheumatoid

treatments

and

well

systemic

as

lupus

non-oncological

myometrial fibrosis, and endometrial injury[2].
Benign diseases
Benign

conditions

such

as

various

hematological diseases such as aplastic anemia and

hematological and autoimmune disorders may

thalassemia, besides various ovarian disorders,

necessitate chemotherapy, radiation, and even

often necessitate treatments which can adversely

bone

[1]

affect future fertility .
There

are

various

marrow

transplantation

for

their

[1]

management, which can result in POI .
fertility

preservation

Bilateral benign ovarian tumors, recurrent

modalities that can be proposed depending on

ovarian torsion, and recurrent or severe ovarian

several factors including the nature of the

endometriosis can also threaten future fertility[1].

pathology, the age of the patient, the required

Ovarian endometriomas are capable of inducing

treatments, the urgency of such treatments, and

local intraovarian inflammation and can trigger

[3]

whether there is a partner . Some of these

follicular atresia with subsequent reduction in the

modalities have already shown their effectiveness

ovarian reserve[5]. Furthermore, there is a rising
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on

exhaustion) has been anticipated to implicate

endometriomas causes considerable impairment in

preservation of the female childbearing potential in

evidence

that

performing

cystectomy

the ovarian reserve . Other indications for fertility

such cases[6].

preservation include family history of POI and

The current strategies for female fertility

[5]

turner syndrome[3].

preservation
Current techniques of fertility preservation

Social reasons
The age at which females are attempting their

include cryopreservation of embryos, oocytes or

first pregnancy now has been steadily increasing,

ovarian tissues, ovarian transposition, gonadal

thus, age-related fertility decline or personal

shielding, ovarian suppression, and conservative

causes has evolved as an indication for elective

surgery[4](Figure 1 & Table 1).

fertility preservation[1].
Female fertility decreases significantly after the
age of 35 years, thus, the term ‘AGE banking’
(oocyte

banking

for

anticipated

gamete

Figure 1. Diagram showing the current female fertility preservation modalities [3]. ART, assisted reproductive
technology; GnRH, gonadotrophin-releasing hormone; GV, germinal vesicle; IVF, in vitro fertilization; IVM, in
vitro maturation.
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Table 1. Advantages and disadvantages of different female fertility preservation modalities [4].
Fertility preservation modality
Gonadotropin-releasing
hormone agonists
co-administration during
cancer treatments
Ovarian transposition

Embryo cryopreservation

Oocyte cryopreservation
Ovarian tissue
cryopreservation and
grafting

Advantages
1. Some medical benefits

Disadvantages
1. Controversial efficacy
2. Potential side effects

1. Relatively simple and rapid laparoscopic
procedure

1. Only beneficial in patients undergoing
pelvic radiotherapy

1. Well established
2. No risk of reimplantation of malignant
cells

1. Only practicable in post-pubertal females
with a male partner
2. Requires time for controlled ovarian
hyperstimulation
3. Does not restore ovarian function
1. Only practicable in post-pubertal females
2. Requires time for controlled ovarian
hyperstimulation
3. Does not restore ovarian function
1. Age limitation (<35 years)
2. Invasive surgical procedure

1. Well established
2. Practicable in single females
3. No risk of reimplantation of malignant
cells
1. Practicable in pre-pubertal girls
2. Do not delay cancer therapies
3. Restore ovarian function

Embryo and oocyte cryopreservation
Embryo and oocyte cryopreservation are the
most well-established and accepted strategies for
female fertility preservation[4]. However, both
necessitate the female to undergo at least one cycle
of controlled ovarian hyperstimulation (COH) in
order to proceed to oocyte retrieval, therefore, they
can only be offered to post- pubertal females with
enough time to undergo ovarian stimulation[4].
These procedures are not practicable in patients
who need to begin gonadotoxic therapy urgently,
as it takes 10-15 days for COH to trigger multiple
follicular growth and oocytes retrieval[4].
One of the advantages of these techniques is
that they carry no risk of reimplantation of
malignant cells when performed in patients with

in the future[8]. Oocyte cryopreservation (Figure
2B) can also be the perfect choice for those who
have ethical or religious objections to embryo
cryopreservation[8].
For patients who are to undergo in vitro
fertilization (IVF), COH is classically initiated at
the start of the follicular phase of the menstrual
cycle[9]. However, for those seeking fertility
preservation prior to undergoing gonadotoxic
treatments, the initiation of their therapy is usually
time sensitive, making a 4-6 week delay
unacceptable[9]. For such patients, ‘random start’
protocol is hence applied, which involves initiating
COH at any point in the menstrual cycle[10]. By
Utilizing such protocol, patients take 2-3 weeks to
complete the procedure, which is suitable for

malignancy[7]. It is obvious that these modalities
provide the chance of achieving pregnancy, but do
not restore the ovarian function[4].
Embryo cryopreservation requires a male
partner, which brings all the legal and ethical
concerns regarding the fate of the embryos if the
patient died or she and her partner separated[8]. In
contrast, oocyte cryopreservation can be
undertaken by single women and conserves a
woman's chance to procreate with a chosen partner

oncologic patients[10]. Noticeably, this protocol is
shown to be as efficient as the conventional start
protocols[10].

https://mmj.mans.edu.eg/home/vol51/iss3/1
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Ovarian
tissue
cryopreservation
and
autotransplantation
For pre-pubertal girls and women who cannot
postpone the initiation of their anticancer
treatment, cryopreservation of ovarian tissue with
subsequent autotransplantation (Figure 2A) is a
choice for preserving their fertility as it does not
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necessitate COH and hence not significantly
postpone treatment[7].
However, there are certain strict selection
criteria that have to be applied. These include: the
age being <35 years (when the ovarian reserve is
still relatively high), a realistic chance of survival
for 5 years, and at least a 50% risk of developing
POI[11].
A great advantage of such technique is that it
restores not only pregnancy chances, but also the
ovarian function, and hence spontaneous
pregnancy can occur[7]. Furthermore, this modality,
when performed in pre-pubertal girls, can induce
their puberty[7].
Unfortunately, such method presents age
restriction because of the paucity of ovarian
primordial follicles after the age of 35 years[11].

malignant cells reimplantation, especially in the
background of hematological malignancies[7].
Ovarian tissue can be reimplanted inside the
pelvic cavity (orthotopic reimplantation) or outside
the pelvic cavity (heterotopic reimplantation) such
as the forearm and abdominal wall muscles[12].
Orthotopic implantation indicates grafting the
thawed ovarian fragments whether on the exposed
ovarian medulla, if at least one ovary is present
(Figure 3), or in a specially created peritoneal
window if both ovaries are absent[12](Figure 4).
Heterotopic ovarian tissue transplantation might be
preferred in patients with severe pelvic adhesions
or anatomic distortion due to radiotherapy, which
might lead to ischemic injury of the implanted
graft due to impairing its vascularization[7,12].
However, results regarding pregnancy rates are

Moreover, one of the greatest concerns with
ovarian tissue autotransplantation is the risk of

much poorer[12].

Figure 2. Schematic presentation of ovarian tissue cryopreservation (A) and mature oocytes cryopreservation (B)[7].

Published by Mansoura Medical Journal, 2023
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Figure 3. Laparoscopic image showing orthotopic ovarian tissue transplantation on the ovarian medulla [7].
A large piece of ovarian cortex is removed to gain access to the medulla and its vascular network (A–B).
The ovarian fragments are placed on the medulla and covered with Interceed® and fibrin glue (C–D).

Figure 4. Laparoscopic image showing orthotopic ovarian tissue transplantation in a peritoneal window [7].
The incision for the peritoneal window is made on the anterior leaf of the broad ligament in an area where a
vascular network is visible (retroperitoneal vessels) (A). The fragments are placed inside the window and
subsequently covered with Interceed® and fibrin glue (B–D).

Alternative family planning options

fertility preservation modality which can be

These include oocyte donation, gestational

provided to women with uterine factor of

carriers (surrogates), and adoption. For patients

infertility, or those with any contraindication for

with ovarian factor of infertility, oocyte donation

pregnancy in order to achieve motherhood by

with subsequent IVF is an established modality for

using embryos created by themselves or with the

[13]

help of a donor to be transferred to the uterus of a

providing reproduction

. The oocyte from the

carrier[14]. Most

donor is fertilized with the partner's sperm, and the

gestational

resultant embryo is then transferred into the

religion absolutely prohibits the use of third-party

female's uterus

notably,

Islamic

[13]

. Meanwhile, surrogacy is a

https://mmj.mans.edu.eg/home/vol51/iss3/1
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reproductive assistance, such as gamete donation,
surrogacy, and ovarian allotransplantation

[15]

.

their

action

include;

the

suppression

of

hypothalamic pituitary axis which leads to
inhibition of the recruitment of preantral follicles

Minimizing the adverse effects of chemo &

to lessen the decrease in the ovarian reserve[18].

radio therapy on fertility
Shielding

and

ovarian

and their development into antral follicles in order

transposition

Also, reduction of the ovarian perfusion which
results in decreasing the concentrations of the

(Oophoropexy)
In pathologies treated by lower abdominal or

chemotherapeutic agents reaching the ovaries[18].

pelvic irradiation only, patients could benefit from

Moreover, it has been reported that GnRH agonists

using a lead shield to protect their ovaries from the

may prevent chemotherapy-induced menorrhagia

adverse effects of irradiation

[16]

. Moreover, ovarian

by abolishing the monthly menstrual flows[18].

transposition is a surgical procedure that can be

Generally, the use of GnRH agonists as a mean

performed before undergoing pelvic irradiation in

of fertility preservation is still controversial and

order to place the ovaries away from the planned

current guidelines do not support depending on

radiation field

[17]

. However, this approach is not

such modality solely for fertility preservation[18].

always effective due to the radiation scatter[17].

Fertility sparing surgery in gynecologic cancers

Hence, during the procedure, it could be wise to

Cervical cancer

for

There are several available fertility sparing

. An additional limitation of

surgeries for patients with cervical cancer[19].

such modality is the theoretical possibility of the

Patients with stage 1A1 disease can be treated via

presence of malignant cells in the ovaries, hence, it

loop electrosurgical excision procedure (LEEP) or

is necessary to provide counselling to patients

cold knife conization (CKC)[19]. While patients

regarding such risk and to exclude malignancies

with tumor stage of 1A2 and small stage 1B1

with a high risk of ovarian involvement from such

(tumor size <2 cm), could be managed with simple

modality[4]. Furthermore, ovarian failure might

or

result from their migration back into the pelvis

Alternatively, patients with stage IB disease could

take

biopsies

cryopreservation

from

the

ovary

[17]

before completion of the radiotherapy course

[17]

.

radical

trachelectomy,

respectively[19].

be treated with a combination of three courses of

Thus, it is recommended that surgeons place

neoadjuvant

metallic clips at the base of the ovary as a radio-

together with conservative surgery, which is

opaque marker at the time of the operation in order

considered an effective fertility-preserving option

to allow the oncologic radiologist to modify the

for such cases[20].

field of radiation if needed[17].
Gonadotrophin-releasing

chemotherapy

It should be noted that procedures of cervical
hormone

(GnRH)

excision are associated with a significant rise in
the risk of obstetric complications such as preterm

agonists
The use of GnRH agonists is a pharmacological
method

platinum-based

of

ovarian

protection

during

chemotherapy[18]. Anticipated mechanisms for

Published by Mansoura Medical Journal, 2023

delivery and prematurity which is attributed to the
loss of physiological function and anatomical
support of the cervix[20].
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Noticeably, for patients who are to undergo

Federation of Gynecology and Obstetrics (FIGO)

radiation therapy for cervical cancer, it is

stage IA & IB, and borderline ovarian tumors

recommended using high-precision radiotherapy

(BOTs), there are some available options for

modalities such as magnetic resonance imaging

ovarian

(MRI)-guided brachytherapy, as an attempt to

unilateral

preserve the uterus and the ovaries from the

therapeutically safe choice for patients with

radiation effect

preservation.

Amongst

the

salpingo-oophorectomy

options,
is

a

unilateral BOT[23]. In addition, ovarian cystectomy

[20]

.

could be preferred when both ovaries are involved

Endometrial cancer
Currently, there are limited uterine sparing

and complete resection is achievable[23].

approaches for fertile females with endometrial

For early-stage (IA & IB) invasive epithelial

cancer. Options include hormonal therapy with

ovarian cancer, utero-ovarian sparing surgery with

progestins and/or hysteroscopic resection of the

complete peritoneal staging and pelvic/para-aortic

tumor[21]. Such approaches might be proposed to

lymphadenectomy has been shown to be a safe

patients with well differentiated endometrial

therapeutic option with successful pregnancy

adenocarcinoma

outcomes[24].

with

no

evidence

of

lymphovascular space invasion or myometrial

The future strategies for female fertility

invasion on imaging via transvaginal sonography

preservation

[21]

. It should be noticed that such patients

Future strategies (Figure 5) are based on the

have to be monitored with endometrial biopsy

use of new pharmacological agents as well as the

every 3 to 6 months for treatment response, putting

advances in ART, cryotechnologies, novel cell

into consideration that high-risk histological

culture systems, bioengineering, and stem cells[3].

subtypes and higher stages of the disease are not

Potential

or MRI

applicable for such conservative treatment

[21]

.

new

pharmacological

gonadoprotective agents

For early-stage endometrial cancer, studies

As

shown

in

Figure

(5),

various

have revealed that sparing the ovaries at the time

pharmacological gonadoprotective agents have

of hysterectomy could be a safe option that does

been investigated.

not increase the risk of tumor recurrence

[21]

. Since

Sphingosine-1-phosphate (S1P) is an inhibitor

such patients are not capable of achieving

of cell death[25]. It has been revealed that it

spontaneous pregnancy, IVF with subsequent

interferes

embryo transfer to a gestational carrier is an option
that could be proposed

[14]

apoptosis

with

doxorubicin-induced

oocyte

[25]

.

. In addition, uterine

Another potential gonadoprotective agent is

transplantation had resulted in live births and could

imatinib, which is a tyrosine kinase enzyme

be

inhibitor[26]. Its administration in combination with

considered

in

selected

cases

to

allow

pregnancy[22].

cisplatin has shown to preserve murine ovarian

Ovarian cancer

follicles[26].

For reproductive age patients with early-stage
ovarian

cancer

including

the

https://mmj.mans.edu.eg/home/vol51/iss3/1
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estrogen-dependent tumors, has demonstrated
promising

results

[27]

.

Studies

revealed

that

has shown to enhance neovascularization and
decrease apoptosis[31].

during

Additionally, it was revealed that the VEGF

chemotherapy had reduced follicular loss and

111 isoform, which is resistant to proteolysis and

decreased

has a relatively long plasma half-life, enhanced the

tamoxifen

destruction

administered

to

rats

doxorubicin-induced

oocyte

[27]

angiogenesis of sheep ovarian cortical tissues

.

Furthermore, the immune modulator; AS101

transplanted to immunodeficient mice[32].

inhibits the signalling pathway responsible for

Moreover, incubation of human ovarian samples

primordial follicle development and possesses

with basic fibroblast growth factor (bFGF) with

[28]

.

subsequent implantation into immunodeficient

Also, it has been revealed that modifying the

mice has shown to enhance angiogenesis, increase

anti-inflammatory and anti-apoptotic properties

mode of administration of chemotherapeutic agent

granulosa

via encapsulating arsenic trioxide, used to treat

apoptosis[33].

against hematological malignancies, decreased

The artificial ovary

ovarian damage in mice

[29]

Over

.

cell

recent

proliferation

decades,

and

tissue

decrease

and

organ

As regard gene therapy, it was found that mice

bioengineering has offered promising solutions to

deficient in the pro-apoptotic puma and noxa genes

otherwise unsolvable medical problems[34]. The

were protected from radiation-induced follicular

artificial ovary is an extension of such efforts in

atresia, suggesting that such therapy might play a

the field of fertility preservation[34](Figure 6).

role in follicular protection against irradiation[30].

Researchers stated that the artificial ovary

Approaches to improve the life span and

refers to “a temporary surrogate of the natural

quality of grafted ovarian tissue

ovary in which isolated follicles, ovarian stromal

Early post transplantation hypoxia is still a

cells and a combination of growth factors can be

concern due to its adverse effect on follicle

encapsulated together inside a biomaterial‐ based

survival. Therefore, improving vascularization of

scaffold”[35]. Thus, it is suggested that the artificial

the grafted tissue is crucial in order to increase the

ovary is able to play the two roles of the ovary; the

survival rates of the follicles and improve the

exocrine function of female gamete production as

effectiveness

well as the endocrine function of steroid hormone

of

ovarian

tissue

transplantation[31](Figure 5).

secretion[35].

Free-radical scavengers like melatonin and

The two major possible problems following any

vitamin E as well as the component of the

transplantation surgery are ischemic injury and

extracellular matrix; hyaluronan have antioxidant,

immune

anti-inflammatory, and anti-apoptotic effects[31].

transplanted in the artificial ovary are of

Accordingly, host treatment with melatonin in

autologous origin, they do not induce serious

combination with ovarian graft incubation with

immune reaction[36]. However, immune reaction

vascular endothelial growth factor (VEGF)-A,

against the scaffold is still a concern; hence, such

rejection[34].

Since

ovarian

cells

vitamin E, and hyaluronan-based biological glue

Published by Mansoura Medical Journal, 2023

9

Mansoura Medical Journal, Vol. 51 [2023], Iss. 3, Art. 1
Female Fertility Preservation

133

delivery biomaterials should be designed to
minimize the immune response

[36]

E and melatonin was investigated in animal ovary

.

One of the solutions to alleviate ischemia and
reperfusion injury is to use angiogenic biomaterial
or

co-transplantation

of

endothelial

and VEGFs, as well as host treatment with vitamin

transplantation studies and showed to improve
graft outcomes[31].

cells[36].

Additionally, treatment of the graft with vitamin E

Figure 5. Diagram showing the future female fertility preservation modalities [3]. bFGF, basic fibroblast growth
factor; ECTM, decellularized human extracellular matrix; HA, hyaluronan; S1P, sphingosine-1-phosphate;
VEGF, vascular endothelial growth factor.

Figure 6. Schematic presentation of manufacturing and transplanting the artificial ovary [34].

https://mmj.mans.edu.eg/home/vol51/iss3/1
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In vitro maturation (IVM) of immature oocytes
This technique involves collection of immature
oocytes from preantral and small antral ovarian
follicles[37]. Those oocytes can be aspirated in vivo
or collected ex vivo in combination with ovarian
tissue cryopreservation. After that, they are
incubated in a maturation medium, with final
cryopreservation of mature oocytes or embryos
produced via IVF[37](Figure 2A).
Noticeably, IVM can be applied in pre-pubertal
girls, performed regardless of cycle phase, and can
allow pregnancy with decreased risk of malignant
cells reimplantation[37].

Uterine transplantation and ovarian tissue
allotransplantation
Uterine transplantation is not only possible, but
also a live birth has been born from a transplanted
uterus[22]. This helps in achieving pregnancy for
patients with an absolute uterine factor of
infertility[9].
On the other hand, ovarian allotransplantation
is emerging as a potential choice for patients with
ovarian factor of infertility, especially those with
repeated oocyte donation failure[13]. Indeed, this
procedure has been performed between two sisters
and led to the first published live birth after
allografting ovarian tissue[38].

134

Stem cells transplantation
Stem cells transplantation showed promising results
for POI cases as regard clinical, histopathological, and
immunohistochemical outcomes[39].
Interestingly, there was a study on human
subjects in which autologous iliac crest-derived
bone marrow mesenchymal stem cells were
injected into the ovaries of ten women with POI, in
which two women regained menstruation and one
achieved pregnancy with subsequent delivery of a
mature living healthy female baby, named
Zeinab[40](Figure 7). She is the first baby to be
born to a POI mother treated with autologous stem
cells transplantation[40].
Interestingly, researchers succeeded to isolate
oogonial stem cells (OSCs) from human ovaries,
which displayed the essential features of oocytegenerating germline stem cells[41]. This finding
gives a strong impetus to investigate the use of
patient-derived induced pluripotent stem cells
(iPSCs), a type of pluripotent stem cells which can
be generated from adult somatic cells such as skin
fibroblasts and peripheral blood mononuclear cells
via genetic reprogramming, to generate autologous
primitive or pregranulosa cells that would be
aggregated with OSCs to enable de-novo, ex-vivo
generation of autologous human ovarian
tissue[41](Figure 8).

Figure 7. Zeinab's photo, the first baby to be born to a POI mother treated with autologous stem cells
transplantation[40].

Published by Mansoura Medical Journal, 2023
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Figure 8. Working model for ex-vivo generation of autologous human ovarian tissue[41]. iPSCs; induced pluripotent
stem cells.

Conclusion
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